AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a ...

Seaport Research analyst Kenneth Zener upgraded Lennar (LEN) to Buy from Neutral with a $154 price target Discover the Best Stocks and Maximize ...

Eli Lilly wants the most optimal locations to host its new manufacturing facilities in the U.S.—and it’s open to pitche | Eli ...

As STAT’s Helen Branswell writes, mRNA vaccines are the fastest to make and the easiest to mass produce.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest ...

The pharmaceutical firm is growing its presence across three states, creating 3,000 jobs.

Eli Lilly has announced plans to expand its domestic medicine production in the US by establishing four new pharmaceutical ...

In August 2024, the company opened the research and development hub, Lilly Seaport Innovation Center, in Boston's Seaport district, US. "Eli Lilly to expand US pharma manufacturing with four new ...